Company / R&D Expense
Dyne Therapeutics, Inc. R&D Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$281.4M
FY2024
5-year range
$45.2M / $281.4M
FY2020-FY2024
Trend
+33.5%
vs FY2023
Sector context
#65 of 209
Health Care
What the data says
At $281M, Dyne Therapeutics, Inc.'s r&d expense ranks #65 of 209 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $11M in FY2019 to $281M in FY2024.
Based on SEC 10-K filings.
$281M in FY2024 with a 5-year CAGR of +91.1%.
Improved from $143M to $281M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +32.4%
- 5-Year CAGR
- +91.1%
- 10-Year CAGR
- -
Sector benchmark
#65 of 209 in Health CareTop 31% of 209This company $281.4M Sector average $647.6M
▼
-56.5% below sector average
Key checks
Key Insights
- Dyne Therapeutics, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +91.1%, indicating consistent growth.
- In FY2024, r&d expense increased 33.5% year-over-year.
- Ranks #65 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $281.4M | +33.5% |
| FY2023 | $210.8M | +47.6% |
| FY2022 | $142.8M | +17.7% |
| FY2021 | $121.3M | +168.4% |
| FY2020 | $45.2M | +309.4% |
| FY2019 | $11.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026